LYMPHOMAS

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R² regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

The combination of ibrutinib and durvalumab demonstrated a modest clinical benefit for patients with relapsed or refractory follicular lymphoma and germinal center B-cell diffuse large B-cell lymphoma, according to the results of a phase I/II trial.

Viola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Victor A. Chow, MD, discusses findings of a retrospective study that looked at 55 patients with various B-cell lymphomas who progressed after treatment with CD19-specific CAR T cells.

The use of&nbsp;brentuximab vedotin in combination with chemotherapy has been recommended for approval by the&nbsp;European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use as a frontline treatment for&nbsp;adult patients with CD30+ stage IV Hodgkin lymphoma.

Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.

In findings reported during the 2018 ASH Annual Meeting,&nbsp;brentuximab vedotin with conventional chemotherapy significantly improved&nbsp;progression-free survival compared with standard therapy for nonpediatric patients&nbsp;with stage III/IV Hodgkin lymphoma.

According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in&nbsp;<em>Lancet Oncology</em>.

A look back at all the FDA news that happened in the month of November 2018, including several new approvals, priority reviews, a fast track designation, and an accelerated approval, across a variety of cancer types.

Two-year findings from the ZUMA-1 trial showed an overall survival rate of more than 50% from treatment with&nbsp;axicabtagene ciloleucel, a CD19-targeted CAR T-cell therapy&nbsp;in patients with&nbsp;refractory large B cell lymphoma; the median survival had not yet been reached. These data, representing a clear plateau in the survival curve, were presented at the 2018 ASH Annual Meeting.

Lenalidomide in addition to rituximab, called the R² regimen, led to a significant increase in progression-free survival compared with rituximab alone in patients with&nbsp;relapsed/refractory indolent non-Hodgkin lymphoma in results from the phase III AUGMENT trial.

Overall survival was more than doubled when&nbsp;the CD79b-targeted antibody&ndash;drug conjugate polatuzumab vedotin was added to treatment with&nbsp;bendamustine and rituximab for patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma.

Mosunetuzumab, a&nbsp;CD3 and CD20 bispecific antibody, induced complete remission rates over 30% in patients with&nbsp;relapsed/refractory follicular lymphoma and&nbsp;relapsed/refractory diffuse large B-cell lymphoma or transformed follicular lymphoma, and demonstrated a tolerable safety profile, showing promise for these patients with&nbsp;B-cell indolent and aggressive non-Hodgkin lymphomas.&nbsp;

According to findings from the FLYER trial presented at the 2018 ASH Annual Meeting, treatment&nbsp;with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity in younger patients with low-risk diffuse large B-cell lymphoma. The progression-free survival rates were also similar between the 2 arms.&nbsp;

Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.

After a median of 19 months of follow-up, durable objective response rates were sustained with tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma. These updated findings from the phase II JULIET study were presented at the 2018 ASH Annual Meeting.&nbsp;

Two variants of the chemotherapy regimen R-CHOP resulted in comparable overall survival and progression-free survival in patients with previously untreated stage III or IV indolent B-cell lymphoma, including grades 1 to 3 follicular lymphoma, according to a long-term follow-up analysis from a combined phase II/III randomized trial.

The immunomodulating agent lenalidomide induced a complete response in 74% of patients with high tumor burden follicular lymphoma when used in combination with rituximab and a 4-drug chemotherapy regimen, according to a recent study.